Abstract:Hepatitis C virus (HCV) is characterized by a high number of chronic cases owing to an impairment of innate and adaptive immune responses. CD81 on the cell surface facilitates HCV entry by interacting with the E2 envelope glycoprotein. In addition, CD81/E2 binding on immunity-related cells may also influence host response outcome to HCV infection. Here, we performed site-specific amino acid substitution in the front layer of E2 sequence to reduce CD81 binding and evaluate the potential of the resulting immunogen as an HCV vaccine candidate. The modified sE2 protein (F442NYT), unlike unmodified sE2, exhibited a significant reduction in CD81 binding, induced higher levels of proinflammatory cytokines, repressed anti-inflammatory response in primary monocyte-derived macrophages as antigen-presenting cells, and stimulated CD4+ T cell proliferation. Immunization of BALB/c mice with an E1/sE2F442NYT nucleoside-modified mRNA-lipid nanoparticle (mRNA-LNP) vaccine resulted in improved IgG1-to-IgG2a isotype switching, an increase in neutralizing antibodies against HCV pseudotype virus, a B and T cell proliferative response to antigens, and improved protection against infection with a surrogate recombinant vaccinia virus-expressing HCV E1-E2-NS2aa134-966 challenge model compared to E1/unmodified sE2 mRNA-LNP vaccine. Further investigation of the modified E2 antigen may provide helpful information for HCV vaccine development. IMPORTANCE Hepatitis C virus (HCV) E2-CD81 binding dampens protective immune response. We have identified that an alteration of amino acids in the front layer of soluble E2 (sE2) disrupts CD81 interaction and alters the cytokine response. Immunization with modified sE2F442NYT (includes an added potential N-linked glycosylation site and reduces CD81 binding activity)-mRNA-LNP candidate vaccine generates improved proinflammatory response and protective efficacy against a surrogate HCV vaccinia challenge model in mice. The results clearly suggested that HCV E2 exhibits immunoregulatory activity that inhibits induction of robust protective immune responses. Selection of engineered E2 antigen in an mRNA-LNP platform amenable to nucleic acid sequence alterations may open a novel approach for multigenotype HCV vaccine development.

Cross-linking of CD81 by HCV-E2 Protein Inhibits Human Intrahepatic Plasmacytoid Dendritic Cells Response to CpG-ODN

Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C

CD81/CD9 tetraspanins aid plasmacytoid dendritic cells in recognition of hepatitis C virus-infected cells and induction of interferon-alpha.

Hepatitis C Virus Protects Human B Lymphocytes from Fas-Mediated Apoptosis Via E2-CD81 Engagement

Increased PD-L1 Expression and PD-L1/CD86 Ratio on Dendritic Cells Were Associated with Impaired Dendritic Cells Function in HCV Infection.

Stably Silencing Of Cd81 Expression By Small Interfering Rnas Targeting 3 '-Ntr Inhibits Hcv Infection

Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders

A Conserved Domain of HCV E2 Glycoprotein Interacts with Human CD81 and Induces Interferon-Gamma Secretion from Peripheral Blood Mononuclear Cells

Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response

Up-Regulation of Erk and P38 Mapk Signaling Pathways by Hepatitis C Virus E2 Envelope Protein in Human T Lymphoma Cell Line

CD81 suppresses NF-κB signaling and is downregulated in hepatitis C virus expressing cells

Quantitation of Plasmacytoid Dendritic Cells in Chronic Hepatitis B Patients with HBeAg Positivity During PEG-IFN and Entecavir Therapy.

The CD81 partner EWI-2wint inhibits hepatitis C virus entry

PD-1/PD-L1 signal pathway participates in HCV F protein-induced T cell dysfunction in chronic HCV infection

[Impaired Non-Viral Specific Immune Function of Dendritic Cell Does Not Interfere with Clearance and Cytotoxic T Lymphocyte Response to HBV or HCV].

Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner

DCs Pulsed with Novel HLA-A2-restricted CTL Epitopes Against Hepatitis C Virus Induced a Broadly Reactive Anti-Hcv-specific T Lymphocyte Response.

Effect of CpG-ODN and HBsAg on the Phenotype and Function of Monocyte-Derived Dendritic Cells in Chronic Hepatitis B

Lymphocyte Activation Gene 3 Negatively Regulates the Function of Intrahepatic Hepatitis C Virus‐specific CD8+ T Cells

Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells